Purchase this article with an account.
Andrew J. Rong, Ryan A. Gallo, Michelle G. Zhang, Ravi Doddapaneni, Anthony J. Griswold, John Y. Lee, Stefan Kurtenbach, Sander R. Dubovy, David T. Tse, Daniel Pelaez; Establishment and Characterization of a Novel Human Ocular Adnexal Sebaceous Carcinoma Cell Line. Trans. Vis. Sci. Tech. 2021;10(6):34. doi: https://doi.org/10.1167/tvst.10.6.34.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Sebaceous carcinoma (SC) is a malignant eyelid tumor of the ocular adnexa that is primarily treated via surgical excision. Few therapies exist in advanced cases, and medical therapy is limited because of our incomplete understanding of SC biology. Herein, we describe a technique to culture human ocular adnexal SC for use as an in vitro model.
Human ocular adnexal SC tumor cells were isolated from a patient undergoing orbital exenteration surgery and named Bascom Palmer 50 (BP50). They were cultured in Dulbecco's modified Eagle medium/nutrient mixture F-12 supplemented with 10% fetal bovine serum and antibiotics and were maintained at 37°C in humidified 5% CO2. The cells were characterized by immunohistochemistry, exome sequencing, and short tandem repeats analysis. In vitro drug screening against mitomycin-C (MMC) was performed using a cell viability assay.
BP50 grew past 40 passages with a doubling time of 52.3 hours. Immunocytochemical staining revealed expression of SC-associated markers adipophilin, epithelial membrane antigen, p53, and androgen receptor. Whole exome sequencing showed a significant carryover in somatic mutations between the tumor tissue and corresponding cell line, revealing genetic markers consistent with SC. MMC affected cell viability in a dose-dependent manner.
BP50 displays characteristics of ocular adnexal SC and therefore may facilitate improved understanding of SC biology and the high throughput assessment of novel therapeutic compounds and new drug combinatorial approaches targeted for this disease.
Drug screening with MMC against these cells shows in vitro evidence to support its continued clinical use in SC.
This PDF is available to Subscribers Only